Ultragenyx says three patients in phase 1/2 gene therapy study had positive results – MarketWatch
EconoTimes |
Ultragenyx says three patients in phase 1/2 gene therapy study had positive results
MarketWatch Ultragenyx Pharmaceutical Inc. RARE, +0.95% shares rose 2.5% in premarket trade Wednesday after the company said that the first dose cohort of three patients in a phase 1/2 gene therapy study had "positive longer-term safety and efficacy" results … Positive Topline Results Released from Study of Gene Therapy in OTC Deficiency Ultragenyx reports encouraging data from Phase 1/2 study of gene therapy DTX301 in OTC deficiency Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of … |
